Centered on the protein immunoblotting workflow, the company has pioneered the globally original contact imaging core technology, overcoming the limitations of traditional cooled charge-coupled device imaging, including signal attenuation, insufficient resolution, and significant quantitative deviations. The technology is compatible with multiple detection modes including chemiluminescence and isotope, and is adaptable to mainstream experimental applications including Western blot, nucleic acid blot, and dot blot.

The uniqueness of HesiMed AI lies in the fact that it is not an isolated large-model product, but rather the core intelligent engine of Hesicare's tripartite system—comprising a chronic disease software platform, a hardware and reagent platform, and data-driven AI—built over many years. Underpinning this is the wealth of real-world data and clinical scenarios accumulated by Hesicare's DMS, which covers more than 3,000 hospitals across China. These long-term accumulations form the foundational capability of HesiMed AI.

Neither TCM clinics nor TCM hospitals can escape the talent bottleneck plaguing the TCM industry. Beijing TRT Healthcare employs 2,732 licensed physicians, including 30 nationally honored physicians. While renowned physicians can be acquired, they are difficult to replicate; however, the brand effect of Tongrentang plays a significant role in healthcare service scenarios.

On July 7, GENESIGHT, an AI life sciences firm, closed a tens-of-millions-yuan seed round backed solely by lead investor Tsinghua Innovation Ventures with no financial advisor disclosed. Proceeds will fund its core data, modeling and clinical moat development, accelerate partnerships with top-tier Class A tertiary hospitals for commercial rollout, and advance its strategy of building a life science operating system rooted in cell-based world models. Having forged deep ties with multiple top hospitals to build closed-loop clinical datasets, GENESIGHT deploys its technology across three business verticals. It addresses a critical flaw plaguing conventional AI drug discovery: massive late-stage clinical losses, by forecasting human cellular drug efficacy pre-large-scale trials to rebuild pharmaceutical evaluation benchmarks.

BrioHealth Solutions’s pan-European BRIOLIFE trial for its proprietary fully magnetically levitated ventricular assist device BrioVAD won clinical approvals in the Netherlands, Austria and Germany between May and June, advancing multi-center research. Nine European sites have completed investigator training, and the first European BrioVAD implantation took place in the Netherlands. It is China’s only VAD firm with coordinated clinical programs across China, the U.S. and Europe. The six-month fast regulatory clearance hinges on its prebuilt evaluation framework aligned with Western standards. Long monopolized by one global brand, Europe’s mature LVAD market faces disruption from this trial. Managed by its European subsidiary BrioHealth BV, the study will enroll about 60 end-stage heart failure patients at 12 top cardiac centers, with six-month post-implant survival as the primary endpoint.

Santo Therapeutics, a Hangzhou-based biotech, has secured both Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for its gene therapy candidate ST002, targeting NF2-related schwannomatosis (NF2-SWN). This rare genetic disorder, caused by NF2 gene mutations leading to multiple tumors, has long lacked effective treatments. ST002 utilizes a proprietary lentiviral vector to deliver functional NF2 genes directly to tumor cells. Early clinical trials initiated in February 2025 have shown promising safety profiles and positive trends in tumor inhibition. These FDA designations provide significant incentives and underscore a pivotal advancement in addressing the high unmet medical needs of NF2-SWN patients.

VelaVigo (Shanghai) Limited has received IND acceptance from China's CDE for VBC108, the world's first bispecific antibody-drug conjugate (ADC) co-targeting CDH17 and CLDN18.2. Designed to treat gastrointestinal malignancies such as colorectal and gastric cancers, VBC108 utilizes a dual-targeting strategy combined with a topoisomerase I inhibitor payload to enhance tumor selectivity, expand patient coverage, and improve drug delivery efficiency. This milestone marks a significant advancement in addressing the high unmet medical needs in gastrointestinal oncology.

On July 10, 2026, Junshi Biosciences filed a Class 2.2 clinical trial application for its PD-1 inhibitor toripalimab, targeting a globally unapproved indication and marking a true first-in-class expansion. Despite being on the market for eight years with 13 approved indications in China, this filing underscores Junshi's sustained innovation in tumor immunotherapy. The Class 2.2 designation not only provides a four-year market exclusivity advantage but also highlights a broader industry shift from price competition to clinical value. By focusing on perioperative treatments, novel combinations like IO + ADC, and unmet clinical needs, toripalimab continues to lead the evolution of the PD-1 landscape.

Shanghai Bendao Gene Technology Co., Ltd. has begun patient recruitment for a clinical study at the Obstetrics and Gynecology Hospital of Fudan University testing BD114, the world's first gene therapy targeting high-grade squamous intraepithelial lesions of the cervix caused by HPV-16 infection. Led by Professor Sui Long, the trial seeks premenopausal women aged 18 to 50 with confirmed HPV-16 infection, no other high-risk HPV types, and no future fertility needs. Bendao Gene is a biotech company leveraging advanced delivery platforms to develop innovative treatments across multiple therapeutic areas.

Chengdu Olymvax Biopharmaceuticals has disclosed that its recombinant Staphylococcus aureus vaccine, co-developed with the Army Medical University, has completed Phase III unblinding and primary statistical analysis with a protective efficacy of 73.25%, significantly exceeding the pre-specified 60% target. The vaccine, developed using an E. coli expression system, demonstrated favorable safety, tolerability, and immunogenicity profiles. This milestone marks a significant breakthrough in the historically challenging field of Staphylococcus aureus vaccine development, where multiple pharmaceutical giants have previously failed due to the pathogen's complex immune evasion mechanisms.

Centered on the protein immunoblotting workflow, the company has pioneered the globally original contact imaging core technology, overcoming the limitations of traditional cooled charge-coupled device imaging, including signal attenuation, insufficient resolution, and significant quantitative deviations. The technology is compatible with multiple detection modes including chemiluminescence and isotope, and is adaptable to mainstream experimental applications including Western blot, nucleic acid blot, and dot blot.

The uniqueness of HesiMed AI lies in the fact that it is not an isolated large-model product, but rather the core intelligent engine of Hesicare's tripartite system—comprising a chronic disease software platform, a hardware and reagent platform, and data-driven AI—built over many years. Underpinning this is the wealth of real-world data and clinical scenarios accumulated by Hesicare's DMS, which covers more than 3,000 hospitals across China. These long-term accumulations form the foundational capability of HesiMed AI.

The trends toward daily disposable and cosmetic-oriented contact lenses have spurred a surge in new product launches. Among these, particularly noteworthy is a niche market long dominated by international giants: silicone hydrogel lenses, with high oxygen permeability as their core advantage, are poised for a domestic breakthrough.

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

On July 7, GENESIGHT, an AI life sciences firm, closed a tens-of-millions-yuan seed round backed solely by lead investor Tsinghua Innovation Ventures with no financial advisor disclosed. Proceeds will fund its core data, modeling and clinical moat development, accelerate partnerships with top-tier Class A tertiary hospitals for commercial rollout, and advance its strategy of building a life science operating system rooted in cell-based world models. Having forged deep ties with multiple top hospitals to build closed-loop clinical datasets, GENESIGHT deploys its technology across three business verticals. It addresses a critical flaw plaguing conventional AI drug discovery: massive late-stage clinical losses, by forecasting human cellular drug efficacy pre-large-scale trials to rebuild pharmaceutical evaluation benchmarks.

Combined with high-speed acquisition and intelligent algorithms, the platform translates these "current fingerprints" into molecular identity and abundance information. Compared with detection principles that rely on complex optical, amplification, or labeling processes, solid-state nanopores enable direct measurement of the intrinsic physical properties of biological macromolecules, moving away from indirect biochemical reaction-based detection. This approach offers advantages including high sensitivity, fast speed, ease of miniaturization, compatibility with semiconductor processes, and scalability for array-based expansion.

Unlike the domestic endoscope innovations over the past decade, which have primarily focused on "functional endoscopy" directions such as fluorescence, narrow-band imaging, confocal imaging, and 3D imaging, Insy Medical has pursued innovation in product form. However, if wireless endoscopy is understood simply as cutting the cables to make it wireless, that perspective would be too narrow. The wireless endoscope embodies Insy Medical's three core foundational technology capabilities, each addressing real clinical pain points.

For now, Imunopharm continues to rely on its CDMO business for financial support. The prospectus indicates that during the reporting period, the company's operating revenue was primarily derived from the CDMO business conducted by its subsidiary, Cygenta Biotech, with services covering cell therapy products such as CAR-T, TCR-T, and CAR-NK.

At the research, development, and industrialization level, Gestala's Chengdu global headquarters and the world's first ultrasonic brain-computer interface super factory were officially commissioned in June, marking the company's transition from the laboratory phase to a new stage where engineering manufacturing and clinical translation proceed in parallel. Concurrently, with the inauguration of the Shanghai headquarters, the company has established a research, development, and innovation system driven by dual centers in Chengdu and Shanghai, creating the "Neolab" frontier laboratory in the field of brain sciences, and further strengthening its fundamental research capabilities at the intersection of brain sciences and artificial intelligence, as well as its ability to connect with global innovation resources.

What truly determines disease progression, drug response, and cell differentiation are often the subtle signals resulting from the cumulative effects of dozens of genes. Their expression levels are not prominent, and models based solely on superficial fitting will never capture these critical changes.

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

The development of this sector has three distinct milestones: from 2019 to 2021, it was in an exploratory phase, with only a few small-sample clinical trials conducted in China; from 2022 to 2024, it entered a critical period for regulatory approval, during which multiple companies advanced their efforts simultaneously, yet no product obtained NMPA registration certification; in 2025,H&H Healthcare's K-Clip received approval, marking the official start of the commercialization era and serving as a turning point for the sector's development.

This collaboration aims to discover candidate drugs with clinical differentiation advantages for high-potential therapeutic targets. By applying advanced generative AI models to the early stages of drug development, both teams are poised to comprehensively enhance the quality of candidate molecule design and conduct structural optimization, striving to achieve best-in-class efficacy and ideal safety profiles.

According to reports, PRIMEAI's artificial intelligence modules can achieve gross margins of 70% to 80%, with overall delivery gross margins exceeding 60%. This high-profitability business model precisely aligns with pharmaceutical companies' demands for cost reduction and efficiency improvement. In 2026, the company is projected to achieve revenue exceeding RMB 100 million, with total contract value approaching RMB 160 million, marking the entry of its commercialization into a phase of exponential growth.

Alebund Pharmaceuticals (Jiangsu) Limited, a clinical-stage biotech focused on chronic kidney disease treatments, made its debut on the Hong Kong Stock Exchange June 29, 2026, with its stock jumping more than 95% to HK$44 at press time and valuing the firm at roughly HK$15 billion. The IPO is set to raise HK$1.181 billion, with 34% earmarked for the New Drug Application filing and global Phase 3 multi-center studies of flagship asset AP301, 37% allocated to global Phase 2b trials for AP306 alongside progress on pipeline candidates including AP308 and AP303, and 12% designated for capacity expansion at its Yangzhou manufacturing facility and pre-launch commercial preparations for future approved therapies.

It forms an effective portfolio strategy with Keppra: Keppra, as a broad-spectrum foundational medication, covers a wide patient population with epilepsy and provides stable cash flow; Vimpat, as a next-generation specialized product, targets more segmented treatment scenarios with higher efficacy demands, representing future growth potential. This "cornerstone product + growth product" combination effectively balances current revenue with future opportunities.

If Abbisko Therapeutics successfully advances the compound to the agreed-upon milestone, Eli Lilly will have the right to further develop and commercialize it, with a corresponding total potential consideration of $258 million. If Eli Lilly chooses not to advance the compound, Abbisko Therapeutics will retain the right to further develop and commercialize it.

The innovative drug industry is fiercely competitive, with a scarcity of high-quality, differentiated late-stage pipelines, forcing MNCs to pivot toward early-stage projects. Although China's innovative drug R&D system is characterized by being "fast, cost-effective, and efficient," this does not alter the fundamental principles of drug development: late-stage projects have a higher likelihood of successful commercialization, whereas early-stage projects suffer from lower success rates.

Peripheral Drug-Coated Balloons (Peripheral DCBs) are core consumables for peripheral arterial interventional therapy, suitable for various scenarios such as lower extremity vascular stenosis, in-stent restenosis, and arteriovenous fistula lesions. Compared with traditional stents, peripheral DCBs offer advantages including no foreign body residue post-procedure, lower risk of inflammation, and better long-term prognosis.

GlaxoSmithKline’s (GSK) long-acting FGF21 analog, efimosfermin alfa, has received IND acceptance from China’s Center for Drug Evaluation (CDE), marking a major advancement in MASH therapy with once-monthly dosing. Engineered to overcome the short half-life of native FGF21, efimosfermin alfa demonstrates a triple mechanism—reducing liver fat, combating inflammation, and reversing fibrosis. Phase II data published in The Lancet showed that after 24 weeks, 68% of patients achieved MASH resolution without fibrosis worsening, 89% had ≥30% liver fat reduction, and 32% reached full liver fat normalization. The drug’s efficacy is independent of GLP-1 background therapy. Acquired by GSK for up to $2 billion, efimosfermin alfa is now advancing into global Phase III trials (ZENITH-1/2) with over 1,250 planned enrollments, offering new hope for China’s estimated 200–300 million NAFLD patients, 10–20% of whom may progress to MASH.